Patents Examined by Yan Xiao
  • Patent number: 10561738
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 18, 2020
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10550197
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • Patent number: 10525082
    Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: January 7, 2020
    Assignee: Seattle Children's Hospital
    Inventors: Courtney Crane, Michael Jensen, Kara White Moyes, Nicole Lieberman
  • Patent number: 10517937
    Abstract: Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: December 31, 2019
    Assignee: University Health Network
    Inventors: Li Zhang, Jong Bok Lee, Branson Chen
  • Patent number: 10517875
    Abstract: Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: December 31, 2019
    Assignee: Mayo Foundation for Medical Engineering and Research
    Inventor: Haidong Dong
  • Patent number: 10509037
    Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 17, 2019
    Assignee: Eisai, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 10478479
    Abstract: The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: November 19, 2019
    Assignee: JW CREAGENE INC.
    Inventors: Yoon Lee, Young-Mok Kim, So-Yeon Kim, Seung-Soo Han, Yong-Soo Bae
  • Patent number: 10478471
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 19, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10478491
    Abstract: As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 19, 2019
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventor: Samir Khleif
  • Patent number: 10465004
    Abstract: The invention provides antibodies or an antigen-binding portion thereof, which recognize the human Frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject.
    Type: Grant
    Filed: January 1, 2015
    Date of Patent: November 5, 2019
    Assignees: Tel HaShomer Medical Research Infrastructure and Services Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Benjamin Dekel, Naomi Pode-Shakked, Orit Harai-Steinberg, Michal Mark-Danieli, Einav Vax
  • Patent number: 10464997
    Abstract: The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The methods include, inter alia, contacting a reducing agent with engineered cysteine antibody molecules, each of the antibody molecules having at least one capped engineered cysteine residue and at least one interchain disulfide bond and reacting the reducing agent with the antibody molecules under conditions sufficient to uncap engineered cysteine residues and form cap byproducts. The method also includes removing the cap byproduct during the reduction reaction. Substantially all of the interchain disulfide bonds present in the antibody molecules prior to reduction are retained following reduction. Antibody conjugates and methods for preparing antibody conjugates using uncapped antibody preparations are also described.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: November 5, 2019
    Assignee: Seattle Genetics, Inc.
    Inventor: Damon L. Meyer
  • Patent number: 10465009
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 5, 2019
    Assignee: Amgen Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko, Zhulun Wang, Athena Sudom
  • Patent number: 10441596
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • Patent number: 10436788
    Abstract: Described herein are compositions and methods of use of anti-Trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (CTCs) from patients with a Trop-2 positive cancer. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. The compositions and methods are of use to detect, diagnose and/or treat metastatic Trop-2+ cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, rectum, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 8, 2019
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
  • Patent number: 10420816
    Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 24, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10413539
    Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 17, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 10414813
    Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 17, 2019
    Assignees: UNIVERSITÉ DE MONTRÉAL, RSEM, LIMITED PARTNERSHIP
    Inventors: Claude Perreault, Diana Paola Granados, Jean-Sébastien Delisle, Pierre Thibault, Sébastien Lemieux
  • Patent number: 10400043
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 3, 2019
    Assignee: Biogen, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 10398672
    Abstract: Aspects of the disclosure relate to methods that involve activating the Protein Kinase A (PKA) pathway to induce cancer stem cells (CSCs) to undergo a mesenchymal to epithelial transition. Methods provided herein are useful, in some embodiments, because they render CSCs amenable to treatment with conventional cancer therapies. In some embodiments, methods are provided that involve assaying PKA pathway activity to identify compounds that selectively target CSCs.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: September 3, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Diwakar Pattabiraman, Brian Bierie, Wai Leong Tam, Robert A. Weinberg
  • Patent number: 10365282
    Abstract: A method for assessing sarcoma metastasis comprising obtaining a biological sample of the subject, detecting a level of a N-terminal segment of moesin in the biological sample, wherein the level of the N-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing metastasis of sarcoma. The present application also provides a biomarker and a kit for assessing metastasis of sarcoma, and uses of such biomarker. The present application also provides a method of treating sarcoma metastasis.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 30, 2019
    Assignee: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao